OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
June 24, 2013
Global program seeks to confirm biosimilarity to support regulatory submissions in the US and EU.
June 20, 2013
A conversation with Kevin Brady of Alkermes about how high potency APIs are changing the way drugs are developed and manufactured in terms of process, equipment and regulations, including a case study that demonstrates the effective scale up or manufacture of a drug with a highly potent API.
June 19, 2013
A screening method predicts delamination in primary packaging.
Semi-automatic technology aids egg-based influenza vaccine production in smaller facility footprints.
June 14, 2013
PSL has developed a microsphere refiner for microsphere formulation, from small scale processes to commercial production.
June 12, 2013
Aseptic connectors provide the flexibility and robustness needed for modern parenteral manufacturing operations.
The lipid-based method provides a tool for delivery of highly potent, poorly soluble, and unstable APIs. And new in-process capsule printing and shell technologies expand softgels’ applications further.
Conjugated vaccines are meeting the need for longer-lasting immune responses, but the production process is complex, and manufacturers are looking for simpler solutions.
June 11, 2013
EMA's revised guideline on biosimilars containing biotechnology-derived proteins is published for public consultation.
June 10, 2013
Facility will use mammalian cell-culture technology and be ready for operations by 2016.